

Marco Marzioni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/485416/publications.pdf>

Version: 2024-02-01

171
papers

12,615
citations

30070

54
h-index

28297

105
g-index

180
all docs

180
docs citations

180
times ranked

12598
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact on follow-up strategies in patients with primary sclerosing cholangitis. Liver International, 2023, 43, 127-138.	3.9	15
2	Machine learning in primary biliary cholangitis: A novel approach for risk stratification. Liver International, 2022, 42, 615-627.	3.9	7
3	Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. Journal of Hepatology, 2022, 76, 1109-1121.	3.7	119
4	Therapeutic effects of dexamethasone-loaded hyaluronan nanogels in the experimental cholestasis. Drug Delivery and Translational Research, 2022, , 1.	5.8	0
5	TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation. Journal of Hepatology, 2022, 77, 991-1004.	3.7	22
6	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1688-1697.e14.	4.4	30
7	Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models. Journal of Hepatology, 2021, 74, 394-406.	3.7	14
8	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. Journal of Hepatology, 2021, 74, 340-349.	3.7	38
9	The Investigative Therapeutic Pipeline for Cholangiocarcinoma: Insights from Model Systems. , 2021, , 555-575.		0
10	Shear wave elastography and transient elastography in HCV patients after direct-acting antivirals. Radiologia Medica, 2021, 126, 894-899.	7.7	27
11	The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities. Journal of Clinical Medicine, 2021, 10, 1763.	2.4	17
12	Effects of a reorganization of cirrhosis care during the lockdown for SARS-CoV-2 outbreak. JHEP Reports, 2021, 3, 100229.	4.9	1
13	Real-world experience with obeticholic acid in patients with primary biliary cholangitis. JHEP Reports, 2021, 3, 100248.	4.9	33
14	Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Naïve Patients With Primary Biliary Cholangitis: A Dual Cut-Off Approach. Hepatology, 2021, 74, 1496-1508.	7.3	28
15	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. Gastroenterology, 2021, 160, 2483-2495.e26.	1.3	27
16	Inhibition of NAE-dependent protein hyper-NEDDylation in cystic cholangiocytes halts cystogenesis in experimental models of polycystic liver disease. United European Gastroenterology Journal, 2021, 9, 848-859.	3.8	7
17	Role of autophagy in cholangiocarcinoma: Pathophysiology and implications for therapy. World Journal of Clinical Cases, 2021, 9, 6234-6243.	0.8	2
18	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. Journal of Hepatology, 2021, 75, 572-581.	3.7	62

#	ARTICLE	IF	CITATIONS
19	Involvement of Autophagy in Ageing and Chronic Cholestatic Diseases. <i>Cells</i> , 2021, 10, 2772.	4.1	4
20	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 179-187.e6.	4.4	57
21	Aging and the Biological Response to Liver Injury. <i>Seminars in Liver Disease</i> , 2020, 40, 225-232.	3.6	13
22	Locally acquired hepatitis E virus in Marche Italy: Clinical/laboratory features and outcome. <i>Digestive and Liver Disease</i> , 2020, 52, 434-439.	0.9	4
23	Italian Clinical Practice Guidelines on Cholangiocarcinoma – Part I: Classification, diagnosis and staging. <i>Digestive and Liver Disease</i> , 2020, 52, 1282-1293.	0.9	40
24	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. <i>British Journal of Cancer</i> , 2020, 123, 1047-1059.	6.4	37
25	HDL cholesterol protects from liver injury in mice with intestinal specific LXR \pm activation. <i>Liver International</i> , 2020, 40, 3127-3139.	3.9	8
26	Carriers of <i>ABCB4</i> gene variants show a mild clinical course, but impaired quality of life and limited risk for cholangiocarcinoma. <i>Liver International</i> , 2020, 40, 3042-3050.	3.9	15
27	Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets. <i>Liver International</i> , 2020, 40, 1670-1685.	3.9	22
28	Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis. <i>Cells</i> , 2020, 9, 721.	4.1	63
29	Gut–Liver Axis and Inflammasome Activation in Cholangiocyte Pathophysiology. <i>Cells</i> , 2020, 9, 736.	4.1	20
30	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	17.8	1,155
31	Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis. <i>Liver International</i> , 2020, 40, 1408-1414.	3.9	22
32	Italian Clinical Practice Guidelines on Cholangiocarcinoma – Part II: Treatment. <i>Digestive and Liver Disease</i> , 2020, 52, 1430-1442.	0.9	35
33	Functional Heterogeneity of the Intrahepatic Biliary Epithelium. , 2020, , 245-254.		2
34	Research Strands in Dermatology and Gastroenterology Units of Department of Clinical and Molecular Sciences in Polytechnic Marche University. , 2020, , 221-246.		0
35	Nerve Regulation of Cholangiocyte Functions. , 2020, , 199-209.		2
36	Ductular Reaction in Liver Diseases: Pathological Mechanisms and Translational Significances. <i>Hepatology</i> , 2019, 69, 420-430.	7.3	251

#	ARTICLE	IF	CITATIONS
37	Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitis. <i>FASEB Journal</i> , 2019, 33, 10269-10279.	0.5	32
38	GS-02-Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial. <i>Journal of Hepatology</i> , 2019, 70, e1-e2.	3.7	18
39	Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance. <i>Liver International</i> , 2019, 39, 43-62.	3.9	54
40	Epidemiology of primary biliary cholangitis in Italy: Evidence from a real-world database. <i>Digestive and Liver Disease</i> , 2019, 51, 724-729.	0.9	31
41	Aging-Related Expression of Twinfilin-1 Regulates Cholangiocyte Biological Response to Injury. <i>Hepatology</i> , 2019, 70, 883-898.	7.3	9
42	Wnt- β -catenin signalling in liver development, health and disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 121-136.	17.8	341
43	Aging-Related Molecular Pathways in Chronic Cholestatic Conditions. <i>Frontiers in Medicine</i> , 2019, 6, 332.	2.6	9
44	Manipulation of the gut-liver axis by interruption of bile acid recirculation: an option for the treatment of sclerosing cholangitis?. <i>Gut</i> , 2018, 67, 1565-1567.	12.1	3
45	Role of inflammation and proinflammatory cytokines in cholangiocyte pathophysiology. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1270-1278.	3.8	67
46	MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation. <i>Hepatology</i> , 2018, 67, 1420-1440.	7.3	72
47	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. <i>Gut</i> , 2018, 67, 1517-1524.	12.1	42
48	Inflammation and the Gut-Liver Axis in the Pathophysiology of Cholangiopathies. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3003.	4.1	29
49	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , 2018, 391, 2417-2429.	13.7	345
50	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. <i>Infection</i> , 2018, 46, 607-615.	4.7	7
51	Knockout of secretin receptor reduces biliary damage and liver fibrosis in Mdr2 ^{-/-} mice by diminishing senescence of cholangiocytes. <i>Laboratory Investigation</i> , 2018, 98, 1449-1464.	3.7	41
52	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 626-634.	8.1	103
53	Cholangiocytes in health and disease: From basic science to novel treatments. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1217-1219.	3.8	2
54	Knockout of the primary sclerosing cholangitis risk gene Fut2 causes liver disease in mice. <i>Hepatology</i> , 2017, 66, 542-554.	7.3	29

#	ARTICLE	IF	CITATIONS
55	Common issues in the management of patients in the waiting list and after liver transplantation. <i>Digestive and Liver Disease</i> , 2017, 49, 241-253.	0.9	23
56	SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. <i>Journal of Hepatology</i> , 2017, 67, 72-83.	3.7	81
57	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2017, 152, 1975-1984.e8.	1.3	355
58	Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment. <i>Digestive Diseases</i> , 2017, 35, 275-281.	1.9	8
59	EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2017, 67, 145-172.	3.7	889
60	Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. <i>Journal of Hepatology</i> , 2017, 66, 1265-1281.	3.7	87
61	Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. <i>Endoscopy</i> , 2017, 49, 588-608.	1.8	154
62	Primary Biliary Cholangitis: advances in management and treatment of the disease. <i>Digestive and Liver Disease</i> , 2017, 49, 841-846.	0.9	23
63	Nlrp3 Activation Induces Il-18 Synthesis and Affects the Epithelial Barrier Function in Reactive Cholangiocytes. <i>American Journal of Pathology</i> , 2017, 187, 366-376.	3.8	43
64	Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. <i>Hepatology</i> , 2017, 66, 1125-1143.	7.3	218
65	Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD. <i>Scientific Reports</i> , 2017, 7, 12200.	3.3	57
66	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	8.1	15
67	Current Targets for Primary Sclerosing Cholangitis. <i>Current Drug Targets</i> , 2017, 18, 901-907.	2.1	0
68	The secretin/secretin receptor axis modulates liver fibrosis through changes in transforming growth factor α 1 biliary secretion in mice. <i>Hepatology</i> , 2016, 64, 865-879.	7.3	79
69	Lin28 and let-7: roles and regulation in liver diseases. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, G757-G765.	3.4	29
70	Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 261-280.	17.8	964
71	Hepatitis E in a region of Italy: An emerging autochthonous infection?. <i>Digestive and Liver Disease</i> , 2016, 48, 1340-1345.	0.9	11
72	Prevalence and clinical outcome of hepatic haemangioma with specific reference to the risk of rupture: A large retrospective cross-sectional study. <i>Digestive and Liver Disease</i> , 2016, 48, 309-314.	0.9	61

#	ARTICLE	IF	CITATIONS
73	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. <i>Digestive and Liver Disease</i> , 2016, 48, 455-467.	0.9	57
74	Liver Regeneration. , 2015, , 229-241.		0
75	PDX-1 mRNA expression in endoscopic ultrasound-guided fine needle cytoaspirate: Perspectives in the diagnosis of pancreatic cancer. <i>Digestive and Liver Disease</i> , 2015, 47, 138-143.	0.9	8
76	Development and functional characterization of extrahepatic cholangiocyte lines from normal rats. <i>Digestive and Liver Disease</i> , 2015, 47, 964-972.	0.9	10
77	Functional and Structural Features of Cholangiocytes in Health and Disease. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015, 1, 368-380.	4.5	80
78	Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. <i>Journal of Hepatology</i> , 2015, 63, 952-961.	3.7	56
79	HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH. <i>PLoS ONE</i> , 2014, 9, e97136.	2.5	76
80	Cholangiocarcinoma development: The resurgence of bile acids. <i>Hepatology</i> , 2014, 60, 795-797.	7.3	10
81	Activation of the developmental pathway neurogenin-3/microRNA-7a regulates cholangiocyte proliferation in response to injury. <i>Hepatology</i> , 2014, 60, 1324-1335.	7.3	22
82	Role of Cholangiocytes in Primary Biliary Cirrhosis. <i>Seminars in Liver Disease</i> , 2014, 34, 273-284.	3.6	37
83	Italian consensus guidelines for the diagnostic work-up and follow-up of cystic pancreatic neoplasms. <i>Digestive and Liver Disease</i> , 2014, 46, 479-493.	0.9	108
84	Mouse Models of Liver Fibrosis Mimic Human Liver Fibrosis of Different Etiologies. <i>Current Pathobiology Reports</i> , 2014, 2, 143-153.	3.4	24
85	Polycystic liver diseases: advanced insights into the molecular mechanisms. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 750-761.	17.8	80
86	Secretin Stimulates Biliary Cell Proliferation by Regulating Expression of MicroRNA 125b and MicroRNA let7a in Mice. <i>Gastroenterology</i> , 2014, 146, 1795-1808.e12.	1.3	83
87	Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2014, 46, 18-24.	0.9	9
88	Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases. <i>Gut</i> , 2014, 63, 1658-1667.	12.1	55
89	Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. <i>Hepatology</i> , 2014, 59, 1738-1749.	7.3	258
90	Recent advances in the morphological and functional heterogeneity of the biliary epithelium. <i>Experimental Biology and Medicine</i> , 2013, 238, 549-565.	2.4	64

#	ARTICLE	IF	CITATIONS
91	PDX-1/Hes-1 interactions determine cholangiocyte proliferative response to injury in rodents: Possible implications for sclerosing cholangitis. <i>Journal of Hepatology</i> , 2013, 58, 750-756.	3.7	24
92	Liver carcinogenesis: Rodent models of hepatocarcinoma and cholangiocarcinoma. <i>Digestive and Liver Disease</i> , 2013, 45, 450-459.	0.9	87
93	Semaphorin 7A Contributes to TGF- β -Mediated Liver Fibrogenesis. <i>American Journal of Pathology</i> , 2013, 183, 820-830.	3.8	46
94	Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. <i>Genes and Immunity</i> , 2013, 14, 179-186.	4.1	52
95	The significance of genetics for cholangiocarcinoma development. <i>Annals of Translational Medicine</i> , 2013, 1, 28.	1.7	20
96	Angiogenic factors in chronic liver diseases: the effects on hepatic progenitor cells. <i>Hepatobiliary Surgery and Nutrition</i> , 2013, 2, 61-4.	1.5	1
97	New insights in hepatocellular carcinoma: from bench to bedside. <i>Annals of Translational Medicine</i> , 2013, 1, 15.	1.7	12
98	Autocrine regulation of biliary pathology by activated cholangiocytes. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 302, G473-G483.	3.4	10
99	ImmunoChip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. <i>Human Molecular Genetics</i> , 2012, 21, 5209-5221.	2.9	139
100	Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. <i>Genes and Immunity</i> , 2012, 13, 461-468.	4.1	75
101	Endoplasmic Reticulum stress induces hepatic stellate cell apoptosis and contributes to fibrosis resolution. <i>Liver International</i> , 2012, 32, 1574-1584.	3.9	40
102	An oestrogen receptor β -selective agonist exerts anti-neoplastic effects in experimental intrahepatic cholangiocarcinoma. <i>Digestive and Liver Disease</i> , 2012, 44, 134-142.	0.9	34
103	Interobserver agreement in contrast harmonic endoscopic ultrasound. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1063-1069.	2.8	31
104	Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the "Cholangiocarcinoma" committee of the Italian Association for the Study of Liver disease. <i>Digestive and Liver Disease</i> , 2011, 43, 60-65.	0.9	59
105	Hernia of Morgagni and Mediastinal Lipoma: A Case Report. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2011, 17, 77-80.	0.8	2
106	Castration inhibits biliary proliferation induced by bile duct obstruction: novel role for the autocrine trophic effect of testosterone. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, G981-G991.	3.4	16
107	Knockout of the neurokinin-1 receptor reduces cholangiocyte proliferation in bile duct-ligated mice. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, G297-G305.	3.4	35
108	Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma; its synthesis is reduced favoring cholangiocarcinoma growth. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, G623-G633.	3.4	46

#	ARTICLE	IF	CITATIONS
109	Increased local dopamine secretion has growth-promoting effects in cholangiocarcinoma. <i>International Journal of Cancer</i> , 2010, 126, 2112-2122.	5.1	46
110	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. <i>Nature Genetics</i> , 2010, 42, 658-660.	21.4	389
111	Clinical implications of novel aspects of biliary pathophysiology. <i>Digestive and Liver Disease</i> , 2010, 42, 238-244.	0.9	16
112	Recent advances in the regulation of cholangiocyte proliferation and function during extrahepatic cholestasis. <i>Digestive and Liver Disease</i> , 2010, 42, 245-252.	0.9	30
113	Pancreatic Duodenal Homeobox-1 de novo expression drives cholangiocyte neuroendocrine-like transdifferentiation. <i>Journal of Hepatology</i> , 2010, 53, 663-670.	3.7	14
114	Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. <i>Gut</i> , 2009, 58, 990-997.	12.1	58
115	Control of Cholangiocyte Adaptive Responses by Visceral Hormones and Neuropeptides. <i>Clinical Reviews in Allergy and Immunology</i> , 2009, 36, 13-22.	6.5	28
116	Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expression. <i>Liver International</i> , 2009, 29, 1031-1042.	3.9	33
117	Human cholangiocarcinoma development is associated with dysregulation of opioidergic modulation of cholangiocyte growth. <i>Digestive and Liver Disease</i> , 2009, 41, 523-533.	0.9	12
118	Human leukocyte antigen polymorphisms in italian primary biliary cirrhosis: A multicenter study of 664 patients and 1992 healthy controls. <i>Hepatology</i> , 2008, 48, 1906-1912.	7.3	120
119	Hepatic fibrogenesis in response to chronic liver injury: novel insights on the role of cell-cell interaction and transition. <i>Liver International</i> , 2008, 28, 1052-1064.	3.9	99
120	Role of endogenous opioids in modulating HSC activity in vitro and liver fibrosis in vivo. <i>Gut</i> , 2008, 57, 352-364.	12.1	48
121	Serotonin Metabolism Is Dysregulated in Cholangiocarcinoma, which Has Implications for Tumor Growth. <i>Cancer Research</i> , 2008, 68, 9184-9193.	0.9	90
122	Small mouse cholangiocytes proliferate in response to H1 histamine receptor stimulation by activation of the IP ₃ /CaMK I/CREB pathway. <i>American Journal of Physiology - Cell Physiology</i> , 2008, 295, C499-C513.	4.6	125
123	Progesterone stimulates the proliferation of female and male cholangiocytes via autocrine/paracrine mechanisms. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 295, G124-G136.	3.4	39
124	Leptin Enhances Cholangiocarcinoma Cell Growth. <i>Cancer Research</i> , 2008, 68, 6752-6761.	0.9	77
125	Thyroid hormone inhibits biliary growth in bile duct-ligated rats by PLC/IP ₃ /Ca ²⁺ -dependent downregulation of SRC/ERK1/2. <i>American Journal of Physiology - Cell Physiology</i> , 2007, 292, C1467-C1475.	4.6	19
126	Cholangiocyte Injury and Ductopenic Syndromes. <i>Seminars in Liver Disease</i> , 2007, 27, 401-412.	3.6	43

#	ARTICLE	IF	CITATIONS
127	Serum and Biliary Insulin-like Growth Factor I and Vascular Endothelial Growth Factor in Determining the Cause of Obstructive Cholestasis. <i>Annals of Internal Medicine</i> , 2007, 147, 451.	3.9	52
128	Molecular pathology of biliary tract cancers. <i>Cancer Letters</i> , 2007, 250, 155-167.	7.2	45
129	Endogenous opioid peptides and chronic liver disease: From bedside to bench. <i>Journal of Hepatology</i> , 2007, 46, 583-586.	3.7	22
130	Proliferating Cholangiocytes: A Neuroendocrine Compartment in the Diseased Liver. <i>Gastroenterology</i> , 2007, 132, 415-431.	1.3	264
131	Glucagon-Like Peptide-1 and Its Receptor Agonist Exendin-4 Modulate Cholangiocyte Adaptive Response to Cholestasis. <i>Gastroenterology</i> , 2007, 133, 244-255.	1.3	73
132	Selective inhibition of ion transport mechanisms regulating intracellular pH reduces proliferation and induces apoptosis in cholangiocarcinoma cells. <i>Digestive and Liver Disease</i> , 2007, 39, 60-69.	0.9	53
133	Prolactin stimulates the proliferation of normal female cholangiocytes by differential regulation of Ca ²⁺ -dependent PKC isoforms. <i>BMC Physiology</i> , 2007, 7, 6.	3.6	35
134	H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/ELK-1 pathway. <i>Laboratory Investigation</i> , 2007, 87, 473-487.	3.7	77
135	Cytoprotective effects of taurocholic acid feeding on the biliary tree after adrenergic denervation of the liver. <i>Liver International</i> , 2007, 27, 558-568.	3.9	23
136	Novel interaction of bile acid and neural signaling in the regulation of cholangiocyte function. <i>Hepatology Research</i> , 2007, 37, S420-9.	3.4	6
137	Taurocholic acid feeding prevents tumor necrosis factor-alpha-induced damage of cholangiocytes by a PI3K-mediated pathway. <i>Experimental Biology and Medicine</i> , 2007, 232, 942-9.	2.4	12
138	Ca ²⁺ -Dependent Cytoprotective Effects of Ursodeoxycholic and Tauroursodeoxycholic Acid on the Biliary Epithelium in a Rat Model of Cholestasis and Loss of Bile Ducts. <i>American Journal of Pathology</i> , 2006, 168, 398-409.	3.8	68
139	A Model of Insulin Resistance and Nonalcoholic Steatohepatitis in Rats. <i>American Journal of Pathology</i> , 2006, 169, 846-860.	3.8	237
140	Vascular Endothelial Growth Factor Stimulates Rat Cholangiocyte Proliferation Via an Autocrine Mechanism. <i>Gastroenterology</i> , 2006, 130, 1270-1282.	1.3	188
141	Endogenous Opioids Modulate the Growth of the Biliary Tree in the Course of Cholestasis. <i>Gastroenterology</i> , 2006, 130, 1831-1847.	1.3	41
142	Estrogens maintain bile duct mass and reduce apoptosis after biliodigestive anastomosis in bile duct ligated rats. <i>Journal of Hepatology</i> , 2006, 44, 1158-1166.	3.7	16
143	Adrenergic receptor agonists prevent bile duct injury induced by adrenergic denervation by increased cAMP levels and activation of Akt. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, G813-G826.	3.4	55
144	Administration of r-VEGF-A prevents hepatic artery ligation-induced bile duct damage in bile duct ligated rats. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 291, G307-G317.	3.4	67

#	ARTICLE	IF	CITATIONS
145	Nervous and Neuroendocrine regulation of the pathophysiology of cholestasis and of biliary carcinogenesis. <i>World Journal of Gastroenterology</i> , 2006, 12, 3471.	3.3	25
146	Heterogeneity of the intrahepatic biliary epithelium. <i>World Journal of Gastroenterology</i> , 2006, 12, 3523.	3.3	75
147	Î³-Aminobutyric Acid Inhibits Cholangiocarcinoma Growth by Cyclic AMP-Dependent Regulation of the Protein Kinase A/Extracellular Signal-Regulated Kinase 1/2 Pathway. <i>Cancer Research</i> , 2005, 65, 11437-11446.	0.9	85
148	Autocrine/paracrine regulation of the growth of the biliary tree by the neuroendocrine hormone serotonin. <i>Gastroenterology</i> , 2005, 128, 121-137.	1.3	226
149	Hepatoprotective and antifibrotic effect of a new silybin-phosphatidylcholine-Vitamin E complex in rats. <i>Digestive and Liver Disease</i> , 2005, 37, 869-876.	0.9	51
150	The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen Î±1(I), TIMP-1 and MMP-2. <i>Digestive and Liver Disease</i> , 2004, 36, 744-751.	0.9	72
151	cAMP stimulates the secretory and proliferative capacity of the rat intrahepatic biliary epithelium through changes in the PKA/Src/MEK/ERK1/2 pathway. <i>Journal of Hepatology</i> , 2004, 41, 528-537.	3.7	110
152	Î±-1 adrenergic receptor agonists modulate ductal secretion of BDL rats via Ca ²⁺ - and PKC-dependent stimulation of cAMP. <i>Hepatology</i> , 2004, 40, 1116-1127.	7.3	61
153	Selective Na ⁺ /H ⁺ exchange inhibition by cariporide reduces liver fibrosis in the rat. <i>Hepatology</i> , 2003, 37, 256-266.	7.3	44
154	Gastrin reverses established cholangiocyte proliferation and enhanced secretin-stimulated ductal secretion of BDL rats by activation of apoptosis through increased expression of Ca ²⁺ -dependent PKC isoforms. <i>Liver International</i> , 2003, 23, 78-88.	3.9	27
155	Taurohyodeoxycholate- and tauroursodeoxycholate-induced hypercholerisis is augmented in bile duct ligated rats. <i>Journal of Hepatology</i> , 2003, 38, 136-147.	3.7	14
156	Regulation of ERK/JNK/p70S6K in two rat models of liver injury and fibrosis. <i>Journal of Hepatology</i> , 2003, 39, 528-537.	3.7	48
157	Increased susceptibility of cholangiocytes to tumor necrosis factor-Î± cytotoxicity after bile duct ligation. <i>American Journal of Physiology - Cell Physiology</i> , 2003, 285, C183-C194.	4.6	52
158	Taurocholate prevents the loss of intrahepatic bile ducts due to vagotomy in bile duct-ligated rats. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 284, G837-G852.	3.4	46
159	Taurocholate feeding prevents CCl ₄ -induced damage of large cholangiocytes through PI3-kinase-dependent mechanism. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 284, G290-G301.	3.4	35
160	Dopaminergic inhibition of secretin-stimulated choleresis by increased PKC-Î³ expression and decrease of PKA activity. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 284, G683-G694.	3.4	59
161	Functional Heterogeneity of Cholangiocytes. <i>Seminars in Liver Disease</i> , 2002, 22, 227-240.	3.6	99
162	Rearrangement of the cytoskeletal network induced by platelet-derived growth factor in rat hepatic stellate cells: role of different intracellular signalling pathways. <i>Journal of Hepatology</i> , 2002, 36, 179-190.	3.7	22

#	ARTICLE	IF	CITATIONS
163	Bile acid depletion and repletion regulate cholangiocyte growth and secretion by a phosphatidylinositol 3-kinase-dependent pathway in rats. <i>Gastroenterology</i> , 2002, 123, 1226-1237.	1.3	74
164	Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha. <i>Hepatology</i> , 2002, 35, 1041-1052.	7.3	122
165	Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. <i>Journal of Hepatology</i> , 2002, 37, 584-591.	3.7	120
166	Insulin inhibits secretin-induced ductal secretion by activation of PKC alpha and inhibition of PKA activity. <i>Hepatology</i> , 2002, 36, 641-651.	7.3	55
167	Role of apoptosis in development of primary biliary cirrhosis. <i>Digestive and Liver Disease</i> , 2001, 33, 531-533.	0.9	5
168	Intracellular pH regulation and Na ⁺ /H ⁺ exchange activity in human hepatic stellate cells: effect of platelet-derived growth factor, insulin-like growth factor 1 and insulin. <i>Journal of Hepatology</i> , 2001, 34, 378-385.	3.7	35
169	Bile acid feeding increased proliferative activity and apical bile acid transporter expression in both small and large rat cholangiocytes. <i>Hepatology</i> , 2001, 34, 868-876.	7.3	110
170	Presentation, Management and Outcome of Cholangiocarcinoma in Europe: Results From Real-World Patient Registry. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
171	Gastrointestinal disorders as immune-related adverse events. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.8	2